Compare ARI & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARI | GPCR |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2009 | 2023 |
| Metric | ARI | GPCR |
|---|---|---|
| Price | $10.13 | $34.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $10.83 | ★ $69.57 |
| AVG Volume (30 Days) | 828.7K | ★ 1.3M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | ★ 9.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $269,296,000.00 | N/A |
| Revenue This Year | $25.91 | N/A |
| Revenue Next Year | $14.63 | N/A |
| P/E Ratio | $11.44 | ★ N/A |
| Revenue Growth | ★ 67.16 | N/A |
| 52 Week Low | $7.70 | $13.22 |
| 52 Week High | $11.11 | $40.29 |
| Indicator | ARI | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 54.46 | 54.98 |
| Support Level | $10.02 | $30.94 |
| Resistance Level | $10.18 | $36.09 |
| Average True Range (ATR) | 0.15 | 2.50 |
| MACD | 0.03 | -0.48 |
| Stochastic Oscillator | 64.42 | 41.07 |
Apollo Commercial Real Estate Finance Inc is a real estate investment trust that primarily originates, invests in, acquires, and manages commercial first-mortgage loans, subordinate financings, commercial mortgage-backed securities, and other real estate-related debt investments. The subordinate loans and first-mortgage loans account for the vast majority of the portfolio on a cost basis. Property types include residential, retail, healthcare, office, mixed-use, hotel, industrial, multifamily, securities, and other, with residential properties and hotels representing the highest property value. More than a third of the properties are located in New York City, with the other properties located across other regions of the United States, as well as other countries.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.